Comparison of tumor curettage and resection for treatment of giant cell tumor of the bone around the knee joint

Zhang, Sheng; Zhang, Jianhua; Wang, Xin

doi:10.12669/pjms.323.9654

Cited by 13 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For treating giant cell tumours, both resection with reconstruction and intralesional curettage have been widely accepted [24][25][26]. Surgery with/without radiotherapy did not signi cantly improve survival in a previous SEER study [11].…”

Section: Discussionmentioning

confidence: 99%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (HR=9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…For treating giant cell tumours, both resection with reconstruction and intralesional curettage have been widely accepted [24][25][26]. Surgery with/without radiotherapy did not significantly improve survival in a previous SEER study [11].…”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Zhang¹,

Wang

Lin³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors. Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (hazard ratio (HR) =9.99, 95% CI: 1.34-74.80, P =0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P <0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P =0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P =0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P =0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P =0.046). Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with age >34 years, stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival.

show abstract

“…To overcome giant cell tumor, either resection with reconstruction or intralesional curettage has been widely accepted [23][24][25]. The surgery with/without radiotherapy did not significantly improve the survival in the previous SEER study [11].…”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Zhang¹,

Wang

Li³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Background The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) were not investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.68, 95% CI: 2.06-6.57, P<0.001), T2 stage (HR=4.96, 95% CI: 1.57-15.63, P=0.006), distant tumor (HR=3.02, 95% CI: 1.32-6.92, P=0.009), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P<0.001), respectively. Conclusions This large population-based series described the clinical characteristics of the malignant GCTB. Age, T2, distant tumor and extra-skeletal sites were determinant survival factors of the patients with malignant GCTB.

show abstract

Comparison of tumor curettage and resection for treatment of giant cell tumor of the bone around the knee joint

Cited by 13 publications

References 22 publications

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and prognostic factor analyses in malignant giant cell tumour of bone

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Contact Info

Product

Resources

About